Desmopressin Evidence Guide
Desmopressin (DDAVP) is FDA-approved for central diabetes insipidus, primary nocturnal enuresis, and hemostasis in mild hemophilia A/von Willebrand disease type I - a broad indication profile reflecting 40+ years of clinical evidence. Its selectivity for V2 receptors over V1 receptors (versus natural vasopressin) makes it the preferred ADH analog for antidiuretic applications. A highly validated, multi-indication peptide drug.
Our Take
Desmopressin (DDAVP) is FDA-approved for central diabetes insipidus, primary nocturnal enuresis, and hemostasis in mild hemophilia A/von Willebrand disease type I - a broad indication profile reflecting 40+ years of clinical evidence. Its selectivity for V2 receptors over V1 receptors (versus natural vasopressin) makes it the preferred ADH analog for antidiuretic applications. A highly validated, multi-indication peptide drug.
- Best for
- Central diabetes insipidus, nocturnal enuresis, hemostasis in mild hemophilia A/vWD type I, ADH receptor research
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 0.1-0.4mcg IV/subcutaneous or 0.1mg oral (DI); 300mcg intranasal single dose (hemostasis)
Benefits and Evidence
- Central Diabetes Insipidus: Level A, includes human evidence - Gold standard treatment for central diabetes insipidus. Effectively reduces urine output from >10 L/day to normal volumes and controls thirst and polydipsia.
- Nocturnal Enuresis: Level A, includes human evidence - Meta-analyses show significant reduction in wet nights. Complete dryness achieved in approximately 25-30% of children, with significant improvement in many more.
- Hemophilia A / vWD Bleeding: Level A, includes human evidence - Raises factor VIII and vWF levels 2-5 fold within 30-60 minutes. Effective for prevention and treatment of bleeding in mild hemophilia A and type 1 von Willebrand disease.
- Hyponatremia Risk: Level A, includes human evidence - Water retention can cause hyponatremia, potentially leading to seizures. Risk is higher in elderly patients and children. Fluid restriction is essential.
Side Effects and Warnings
- Headache
- Nasal congestion (intranasal)
- Nausea
- Abdominal cramps
- Facial flushing
- Hyponatremia
- Hyponatremia/water intoxication - restrict fluid intake; monitor serum sodium
- Contraindicated in habitual polydipsia
Research Dosage References
- <strong>Intranasal spray</strong> - 10-40 mcg - Once or twice daily - For diabetes insipidus. Typical dose 10-20 mcg at bedtime, with optional morning dose. Titrate based on urine output.
- <strong>Oral tablet</strong> - 0.1-0.4 mg - Two to three times daily - For diabetes insipidus. Start at 0.05 mg twice daily and titrate. Oral bioavailability ~5% of intranasal.
- <strong>Sublingual (melt)</strong> - 60-240 mcg - Once at bedtime - For nocturnal enuresis. Place under tongue. Restrict fluid intake from 1 hour before to 8 hours after dosing.
Mechanism of Action
Desmopressin acts primarily through selective V2 receptor agonism: 1. V2 receptor selectivity: >3000-fold selectivity for V2 over V1a receptors, providing antidiuretic effect without significant vasoconstriction. 2. Aquaporin-2 insertion: V2 receptor activation in renal collecting duct principal cells triggers cAMP cascade, leading to translocation and insertion of aquaporin-2 water channels into the apical membrane. 3. Factor VIII and vWF release: Stimulates release of von Willebrand factor (vWF) and factor VIII from endothelial Weibel-Palade bodies, useful in mild hemophilia A and type 1 von Willebrand disease. 4. Prolonged duration: Resistance to enzymatic degradation (due to deamination) extends half-life to 2-4 hours, allowing practical dosing schedules.
Legal Status
FDA-approved for central diabetes insipidus, primary nocturnal enuresis, hemophilia A, and type 1 von Willebrand disease. Multiple formulations available by prescription. Marketed by various manufacturers including Ferring.
Primary Sources
- Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev, 2002.
- DDAVP in the treatment of central diabetes insipidus. J Intern Med, 2004.
- Desmopressin for the treatment of bleeding disorders. Haemophilia, 2008.